FDA Warns Cornerstone Over Zyflo Marketing
The U.S. Food and Drug Administration has taken Cornerstone Therapeutics Inc. to task over certain advertising materials for Zyflo CR, saying they omit important risk information associated with the asthma treatment....To view the full article, register now.
Already a subscriber? Click here to view full article